Elizabeth Masson-Hurlburt
Corporate Officer/Principal chez CORMEDIX INC.
Fortune : 192 483 $ au 31/03/2024
Profil
Elizabeth Masson-Hurlburt is currently the Chief Clinical Strategy & Operations Officer at CorMedix, Inc. Prior to her current position, she worked as the Vice President-Clinical Operations at Gemphire Therapeutics, Inc. from 2016 to 2018.
Ms. Masson-Hurlburt completed her undergraduate degree at Bay Path College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CORMEDIX INC.
0,08% | 12/01/2024 | 45 397 ( 0,08% ) | 192 483 $ | 31/03/2024 |
Postes actifs de Elizabeth Masson-Hurlburt
| Sociétés | Poste | Début |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - |
Anciens postes connus de Elizabeth Masson-Hurlburt
| Sociétés | Poste | Fin |
|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/03/2018 |
Formation de Elizabeth Masson-Hurlburt
| Bay Path College | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
